IHT Wealth Management LLC Has $330,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

IHT Wealth Management LLC lowered its position in Boston Scientific Co. (NYSE:BSX) by 30.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,699 shares of the medical equipment provider’s stock after selling 1,624 shares during the quarter. IHT Wealth Management LLC’s holdings in Boston Scientific were worth $330,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Parnassus Investments LLC boosted its stake in Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider’s stock worth $1,327,000 after buying an additional 97 shares in the last quarter. Evergreen Capital Management LLC lifted its holdings in shares of Boston Scientific by 1.7% during the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider’s stock worth $565,000 after acquiring an additional 106 shares during the period. PDS Planning Inc boosted its position in shares of Boston Scientific by 1.5% during the 4th quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider’s stock valued at $668,000 after acquiring an additional 113 shares in the last quarter. Adero Partners LLC increased its stake in Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 120 shares during the period. Finally, Tradition Wealth Management LLC raised its position in Boston Scientific by 2.2% in the fourth quarter. Tradition Wealth Management LLC now owns 5,510 shares of the medical equipment provider’s stock worth $492,000 after purchasing an additional 121 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 15,087 shares of Boston Scientific stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the transaction, the chief financial officer now directly owns 241,451 shares in the company, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 138,009 shares of company stock valued at $14,407,381. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Up 0.8 %

Shares of NYSE BSX opened at $101.96 on Friday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $150.81 billion, a PE ratio of 81.57, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The firm’s 50-day moving average is $98.68 and its 200-day moving average is $94.86. Boston Scientific Co. has a 1 year low of $70.97 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BSX. Morgan Stanley upped their price objective on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. UBS Group upped their price target on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research report on Friday, January 10th. Royal Bank of Canada boosted their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $114.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.